Hybrid Cell Membrane-Functionalized Biomimetic Nanoparticles for Targeted Therapy of Osteosarcoma

References

• Picci P. Osteosarcoma (osteogenic sarcoma). Orphanet J Rare Dis. 2007;2:6. doi:10.1186/1750-1172-2-6
   PubMed Web of Science ®Google Scholar
• Casali PG, Bielack S, Abecassis N, et al. Bone sarcomas: ESMO-PaedCan-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl4):iv79–iv95. doi:10.1093/annonc/mdy310
   PubMed Web of Science ®Google Scholar
• Coleman R, Hadji P, Body JJ, et al. Bone health in cancer: ESMO clinical practice guidelines. Ann Oncol. 2020;31(12):1650–1663. doi:10.1016/j.annonc.2020.07.019
   PubMed Web of Science ®Google Scholar
• Wang SY, Hu HZ, Qing XC, Zhang ZC, Shao ZW. Recent advances of drug delivery nanocarriers in osteosarcoma treatment. J Cancer. 2020;11(1):69–82. doi:10.7150/jca.36588
   PubMed Web of Science ®Google Scholar
• Zhang YN, Poon W, Tavares AJ, McGilvray ID, Chan WCW. Nanoparticle-liver interactions: cellular uptake and hepatobiliary elimination. J Control Release. 2016;240:332–348. doi:10.1016/j.jconrel.2016.01.020
   PubMed Web of Science ®Google Scholar
• Oldenborg PA, Zheleznyak A, Fang YF, Lagenaur CF, Gresham HD, Lindberg FP. Role of CD47 as a marker of self on red blood cells. Science (New York, NY). 2000;288(5473):2051–2054. doi:10.1126/science.288.5473.2051
   Google Scholar
• Hu CM, Zhang L, Aryal S, Cheung C, Fang RH, Zhang L. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc Natl Acad Sci U S A. 2011;108(27):10980–10985. doi:10.1073/pnas.1106634108
   PubMed Web of Science ®Google Scholar
• Zhai Y, Su J, Ran W, et al. Preparation and application of cell membrane-camouflaged nanoparticles for cancer therapy. Theranostics. 2017;7(10):2575–2592. doi:10.7150/thno.20118
   PubMed Web of Science ®Google Scholar
• Lei Y, Junxin C, Yongcan H, Xiaoguang L, Binsheng Y. Role of microRNAs in the crosstalk between osteosarcoma cells and the tumour microenvironment. J Bone Oncol. 2020;25:100322. doi:10.1016/j.jbo.2020.100322
   PubMed Web of Science ®Google Scholar
• Huang Q, Liang X, Ren T, et al. The role of tumor-associated macrophages in osteosarcoma progression - therapeutic implications. Cell Oncol. 2021;44(3):525–539. doi:10.1007/s13402-021-00598-w
   PubMed Web of Science ®Google Scholar
• Xia Y, Rao L, Yao H, Wang Z, Ning P, Chen X. Engineering macrophages for cancer immunotherapy and drug delivery. Adv Mater. 2020;32(40):e2002054. doi:10.1002/adma.202002054
   PubMed Web of Science ®Google Scholar
• Xuan M, Shao J, Dai L, He Q, Li J. Macrophage cell membrane camouflaged mesoporous silica nanocapsules for in vivo cancer therapy. Adv Healthcare Mater. 2015;4(11):1645–1652. doi:10.1002/adhm.201500129
   Web of Science ®Google Scholar
• Xuan M, Shao J, Dai L, Li J, He Q. Macrophage cell membrane camouflaged au nanoshells for in vivo prolonged circulation life and enhanced cancer photothermal therapy. ACS Appl Mater Interfaces. 2016;8(15):9610–9618. doi:10.1021/acsami.6b00853
   PubMed Web of Science ®Google Scholar
• Sun H, Su J, Meng Q, et al. Cancer-cell-biomimetic nanoparticles for targeted therapy of homotypic tumors. Adv Mater. 2016;28(43):9581–9588. doi:10.1002/adma.201602173
   PubMed Web of Science ®Google Scholar
• Harris JC, Scully MA, Day ES. Cancer cell membrane-coated nanoparticles for cancer management. Cancers. 2019;11(12):1836. doi:10.3390/cancers11121836
   PubMed Web of Science ®Google Scholar
• Wang D, Dong H, Li M, et al. Erythrocyte-cancer hybrid membrane camouflaged hollow copper sulfide nanoparticles for prolonged circulation life and homotypic-targeting photothermal/chemotherapy of melanoma. ACS nano. 2018;12(6):5241–5252. doi:10.1021/acsnano.7b08355
   PubMed Web of Science ®Google Scholar
• Suski JM, Lebiedzinska M, Wojtala A, et al. Isolation of plasma membrane-associated membranes from rat liver. Nat Protoc. 2014;9(2):312–322. doi:10.1038/nprot.2014.016
   PubMed Web of Science ®Google Scholar
• Lai P, Daear W, Löbenberg R, Prenner EJ. Overview of the preparation of organic polymeric nanoparticles for drug delivery based on gelatine, chitosan, poly(d,l-lactide-co-glycolic acid) and polyalkylcyanoacrylate. Colloids Surf B Biointerfaces. 2014;118:154–163. doi:10.1016/j.colsurfb.2014.03.017
   PubMed Web of Science ®Google Scholar
• Liao Y, Zhang Y, Blum NT, Lin J, Huang P. Biomimetic hybrid membrane-based nanoplatforms: synthesis, properties and biomedical applications. Nanoscale Horiz. 2020;5(9):1293–1302. doi:10.1039/D0NH00267D
   PubMed Web of Science ®Google Scholar
• Liu WL, Zou MZ, Liu T, et al. Cytomembrane nanovaccines show therapeutic effects by mimicking tumor cells and antigen presenting cells. Nat Commun. 2019;10(1):3199. doi:10.1038/s41467-019-11157-1
   PubMed Web of Science ®Google Scholar
• Fang RH, Hu CM, Luk BT, et al. Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery. Nano Lett. 2014;14(4):2181–2188. doi:10.1021/nl500618u
   PubMed Web of Science ®Google Scholar
• Boonstra MC, de Geus SW, Prevoo HA, et al. Selecting targets for tumor imaging: an overview of cancer-associated membrane proteins. Biomark Cancer. 2016;8:119–133. doi:10.4137/BIC.S38542
   PubMedGoogle Scholar
• Lu KH, Chen PN, Hsieh YH, et al. 3-Hydroxyflavone inhibits human osteosarcoma U2OS and 143B cells metastasis by affecting EMT and repressing u-PA/MMP-2 via FAK-Src to MEK/ERK and RhoA/MLC2 pathways and reduces 143B tumor growth in vivo. Food Chem Toxicol. 2016;97:177–186. doi:10.1016/j.fct.2016.09.006
   PubMed Web of Science ®Google Scholar
• Gharbavi M, Johari B, Mousazadeh N, et al. Hybrid of niosomes and bio-synthesized selenium nanoparticles as a novel approach in drug delivery for cancer treatment. Mol Biol Rep. 2020;47(9):6517–6529. doi:10.1007/s11033-020-05704-z
   PubMed Web of Science ®Google Scholar
• Gharbavi M, Johari B, Rismani E, Mousazadeh N, Taromchi AH, Sharafi A. NANOG decoy oligodeoxynucleotide-encapsulated niosomes nanocarriers: a promising approach to suppress the metastatic properties of U87 human glioblastoma multiforme cells. ACS Chem Neurosci. 2020;11(24):4499–4515. doi:10.1021/acschemneuro.0c00699
   PubMed Web of Science ®Google Scholar
• Horwitz SB. Mechanism of action of taxol. Trends Pharmacol Sci. 1992;13(4):134–136. doi:10.1016/0165-6147(92)90048-B
   PubMed Web of Science ®Google Scholar
• Zhang W, Wang M, Tang W, et al. Nanoparticle-laden macrophages for tumor-tropic drug delivery. Adv Mater. 2018;30(50):e1805557. doi:10.1002/adma.201805557
   PubMed Web of Science ®Google Scholar
• Hu C, Lei T, Wang Y, et al. Phagocyte-membrane-coated and laser-responsive nanoparticles control primary and metastatic cancer by inducing anti-tumor immunity. Biomaterials. 2020;255:120159. doi:10.1016/j.biomaterials.2020.120159
   PubMed Web of Science ®Google Scholar
• Miki I, Kusano A, Ohta S, et al. Histamine enhanced the TNF-alpha-induced expression of E-selectin and ICAM-1 on vascular endothelial cells. Cell Immunol. 1996;171(2):285–288. doi:10.1006/cimm.1996.0205
   PubMed Web of Science ®Google Scholar
• Usami Y, Ishida K, Sato S, et al. Intercellular adhesion molecule-1 (ICAM-1) expression correlates with oral cancer progression and induces macrophage/cancer cell adhesion. Int J Cancer. 2013;133(3):568–578. doi:10.1002/ijc.28066
   PubMed Web of Science ®Google Scholar
• Chao MP, Weissman IL, Majeti R. The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications. Curr Opin Immunol. 2012;24(2):225–232. doi:10.1016/j.coi.2012.01.010
   PubMed Web of Science ®Google Scholar
• Barkat MA, Beg S, Pottoo FH, Ahmad FJ. Nanopaclitaxel therapy: an evidence based review on the battle for next-generation formulation challenges. Nanomed. 2019;14(10):1323–1341. doi:10.2217/nnm-2018-0313
   PubMed Web of Science ®Google Scholar